Dr. Ariel Weinberger




  1. Home
  2. Speakers
  3. Speaker Detail
photo of Dr. Ariel Weinberger

Autonomous Therapeutics, Inc.

Dr. Ariel Weinberger

Dr. Weinberger is the Founder & CEO of Autonomous Therapeutics—a startup developing the first mutating therapeutics to indefinitely control rapidly evolving infectious diseases. Whereas state-of-the-art therapies are static compounds, Dr. Weinberger and colleagues are designing therapeutics that mutate along with viruses to confer lifelong, ‘resistance-proof’ control. These Therapeutic Interfering Particles (TIPs) have now been developed against HIV, Influenza and Zika—and can be engineered against any virus in just weeks.


Prior to founding Autonomous, Dr. Weinberger was a Principal Investigator and Wyss Institute Fellow at Harvard Medical School. His work at Harvard focused on the theoretical underpinnings of resistance-proof interventions, including the design requirements that enable lifelong, co-evolutionary control. Dr. Weinberger also developed the first models of CRISPR-Cas systems—developing a leading theory to explain the loss of CRISPR-Cas immunity in >50% of bacteria. He received his Ph.D. in Biophysics at UC Berkeley, studying the impact of first-in-class HIV antivirals and, more generally, virus-immune system co-evolution. For his graduate work, Dr. Weinberger received the California HIV/AIDS Dissertation Award. As a graduate student, he performed research at leading U.S. and international laboratories, including: NIH, the Los Alamos National Laboratory, the Spanish National Cancer Institute, and the Navy Research Laboratory.


Dr. Weinberger’s awards include: the Wyss Fellowship (Harvard), the Ruth L. Kirschstein Award (NIH), the NDSEG Fellowship (DoD), the VIGRE Award (NSF), the Strauss and Banneker-Key Scholarships (UMD). He has been a leading author on high-profile scientific articles, including in: Cell, mBio, Trends in Biotechnology, Cell Host and Microbe, and PLoS.